NIHON TRIM CO.,LTD.

With approximately 850,000 active alkaline ionizer users, sales of water purification cartridges, a consumable product, grew steadily to ¥5,847 million (up 4.2% year on year) in FY2026 (ending March 2026). Customer service through regular information distribution and follow-up calls supports the repeat purchase rate, forming a stable revenue base that is less susceptible to economic fluctuations.

Subsidiary Stem Cell Institute holds approximately 99% share of the total domestic cord blood storage volume, making it Japan's largest private cord blood bank. As of the end of March 2026, the cumulative number of stored samples exceeded 110,000, establishing a stock-type business model that generates ongoing storage fee revenue throughout the contract period. Following the introduction of a new storage plan in November 2024, sales for the fiscal year under review reached a record high.

Since its founding in 1982, the company has continued joint industry-academia-government research with National Taiwan University, Kyushu University, Tohoku University, Kobe University, Waseda University, RIKEN, and others. The effect of electrolyzed hydrogen water in "improving gastrointestinal symptoms" has been certified as a controlled medical device under the jurisdiction of the Ministry of Health, Labour and Welfare. In February 2025, the results of joint research with Waseda University were published in an international academic journal, and the continuous accumulation of such evidence serves as a barrier to entry for competitors.

In the Workplace Sales Division, the mainstay of direct sales, the Company is strengthening recruitment with a target of a 150-person sales force (up 22.0% from the previous fiscal year-end) within FY2026 (ending March 2026). It will pursue medium- to long-term initiatives including strengthening sales capability, further deepening penetration in the sports and beauty fields, developing new sales channels, new product development, and reinforcing scientific evidence.

At PT. SUPER WAHANA TEHNO, construction of a new proprietary plant is underway to meet growing demand. The Company aims to bring it into operation during FY2027 (ending March 2027), thereby strengthening production capacity, improving management efficiency, and building a stable supply system. It also plans to change the material of gallon bottles during FY2026 (ending March 2026) in response to consumers' heightened health awareness.

The Company expects to newly introduce the system at 5 facilities in FY2027 (ending March 2027), expanding from the current 37 facilities and 1,127 beds. It is developing new candidate sites for introduction through active participation in academic conferences such as those of the Japanese Society for Dialysis Therapy, strengthened collaboration with distributors, and enhanced outreach to dialysis patients. It will continue to strengthen scientific evidence and improve dialysis equipment, aiming to expand adoption as a next-generation global standard therapy.

In the regenerative medicine field, in addition to further growth of existing domestic businesses, the Company is vigorously pursuing full-scale overseas expansion centered on Singapore and new business development. Taking into account the moves of competitors in the Singapore market, the Company regards this as a critical investment phase for future market development and is making proactive upfront investments. It plans to renew its record-high sales again in FY2027 (ending March 2027).

With the alkaline ionizer sales business as its core, the Company is vigorously developing the Bottled Water business, the Electrolyzed Water Dialysis System business, and the regenerative medicine field, aiming to achieve its medium-term management plan. As a capital policy, it targets ROE of 10% or higher and implements progressive dividends based on a DOE of 4%. The dividend forecast for FY2027 (ending March 2027) is ¥130 per share (DOE 4.0%, payout ratio 44.5%).